03:45 , Apr 13, 2018 |  BC Innovations  |  Targets & Mechanisms

Meeting the burden

A major theme at this year’s AACR is the abundance of preclinical discovery driven by molecular signatures in patient samples, suggesting the research community is heeding the call for studies better grounded in human data,...
08:00 , Feb 11, 2013 |  BioCentury  |  Finance

Bubbling up in Japan

Japan's biotech stocks have benefited from a spike in interest from retail investors driven in part by last October's Nobel Prize for a Kyoto University stem cell researcher. Company executives who spoke with BioCentury are...
07:00 , Jun 11, 2012 |  BC Week In Review  |  Clinical News

CBP501: Preliminary Phase II data

Preliminary data from an open-label, international Phase II trial in 65 chemotherapy-naïve patients with unresectable MPM showed that 25 mg/m 2 IV CBP501 plus cisplatin and pemetrexed on day 1 of a 21-day cycle met...
00:47 , Jun 5, 2012 |  BC Extra  |  Clinical News

CanBas' CBP501 meets mesothelioma endpoint

CanBas Co. Ltd. (Tokyo:4575) said CBP501 plus cisplatin and pemetrexed met the primary endpoint of a progression-free survival rate greater than 55% at four months in a Phase II trial to treat malignant pleural mesothelioma...
08:00 , Jan 16, 2012 |  BC Week In Review  |  Clinical News

CBP501 regulatory update

FDA granted Orphan Drug designation for CanBas' CBP501 to treat mesothelioma in combination with cisplatin and pemetrexed. CanBas expects to complete a Phase II trial evaluating the product plus cisplatin and pemetrexed for first-line treatment...
08:00 , Nov 7, 2011 |  BC Week In Review  |  Clinical News

CBP501: Completed Phase II enrollment

CanBas completed enrollment of 63 chemotherapy-naïve patients in an open-label, international Phase II trial comparing IV CBP501 plus cisplatin and pemetrexed vs. pemetrexed and cisplatin alone. Eli Lilly and Co. (NYSE:LLY, Indianapolis, Ind.) markets Alimta...
08:00 , Nov 7, 2011 |  BC Week In Review  |  Clinical News

CBP501: Completed Phase II enrollment

CanBas completed enrollment of 192 patients in an open-label, international Phase II trial comparing 25 mg/m 2 IV CBP501 in combination with 500 mg/m 2 IV pemetrexed and 75 mg/m 2 IV cisplatin given on...
07:00 , Jul 18, 2011 |  BioCentury  |  Finance

RaQualia scores

RaQualia scores In one of the largest biotech IPOs ever in Japan, RaQualia Pharma Inc. last week raised ¥6.4 billion ($79.4 million), giving it a post-money valuation of ¥21.5 billion ($266.6 million) and putting its...
08:00 , Jan 4, 2010 |  BioCentury  |  Finance

IPO performance

IPO performance Company Date Raised Post-$ 12/31 mcap % chg Human Stem Cells Institute(MICEX:ISKJ) 12/10/09 $4.8 $23.9 $46.7 95% China Nuokang Bio-Pharmaceutical Inc. (NASDAQ:NKBP) 12/9/09 $40.7 $177.1 $154.6 -13% T-Ray Science Inc. (TSX-V:THZ) 12/9/09 $1.4...
07:00 , Oct 19, 2009 |  BioCentury  |  Finance

Ebb & Flow

Armed with two Special Protocol Agreements from FDA, Amarin Corp. (NASDAQ:AMRN) has been able to resurrect its fortunes by convincing investors that a compound that disappointed in its original indication of Huntington's disease deserves a...